非甾体抗炎药使用与年龄相关性黄斑变性风险:多中心队列分析
本研究基于TriNetX多中心电子病历数据库的回顾性队列,纳入63万余对倾向评分匹配的NSAID处方者与非使用者,发现NSAID使用与AMD风险降低相关(HR 0.58,95%CI 0.56-0.59),且在不同时间点、阿司匹林及非选择性COX-2抑制剂亚组、以及干性和湿性AMD亚型中均观察到保护性关联。
要点
- NSAID处方者AMD风险低于非使用者(HR 0.58,95%CI 0.56-0.59)。
- 保护效应在6个月至5年各时间点均持续存在。
- 阿司匹林和非选择性COX-2抑制剂亚组均显示AMD风险降低。
核心结论
- 与非使用者相比,接受NSAID处方的患者未来发生AMD的风险降低。
研究设计与样本
- 回顾性队列研究,使用TriNetX去标识化多中心电子病历数据库2015年1月1日至2024年12月31日数据。
- NSAID处方队列与无NSAID使用史的随机对照组按1:1倾向评分匹配,匹配因素包括年龄、性别、种族及吸烟等选定合并症。
主要发现
- NSAID使用者AMD风险降低:6个月HR 0.31(95%CI 0.27-0.36),1年HR 0.36(95%CI 0.33-0.39),3年HR 0.42(95%CI 0.40-0.44),5年HR 0.48(95%CI 0.47-0.50)。
- 总体AMD风险HR 0.58(95%CI 0.56-0.59)。
- 阿司匹林处方者AMD风险HR 0.72(95%CI 0.69-0.75),非选择性环氧合酶-2抑制剂处方者HR 0.41(95%CI 0.36-0.46)。
- 非渗出性AMD风险HR 0.56(95%CI 0.55-0.58),渗出性AMD风险HR 0.62(95%CI 0.59-0.65)。
临床怎么用
- 对于有AMD风险的患者,NSAID处方可能与较低的AMD发生风险相关,但需结合个体情况权衡用药获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the effect of nonsteroidal anti-inflammatory drug (NSAID) use and the risk of age-related macular degeneration (AMD). DESIGN: Retrospective cohort study using a de-identified multicenter electronic medical records database. PARTICIPANTS: This study included patients who received prescriptions for NSAIDs and individuals who did not to assess for the effects of NSAID prescriptions on future AMD risk. METHODS: Data from the TriNetX database between January 1, 2015, and December 31, 2024, were used to identify patients who were prescribed NSAIDs with no prior history of AMD. The NSAID patient cohort was propensity score-matched in a 1:1 ratio with a control group of randomly selected patients without a history of NSAID use, based on age, sex, race, and selected comorbidities of interest, including smoking and other common adult comorbidities that potentially could affect future AMD risk. MAIN OUTCOME MEASURES: Cumulative incidence and hazard ratio (HR) of AMD. RESULTS: Six hundred thirty-four thousand seven hundred ninety-four patients who were prescribed NSAIDs (mean ± standard deviation age, 59.93 ± 11.95 years) and 634 794 patients who were not prescribed NSAIDs (mean ± standard deviation age, 59.68 ± 12.15 years) were recruited. Among NSAID users, decreased risk of AMD development was seen at 6 months (HR, 0.31; 95% confidence interval [CI], 0.27-0.36), 1 year (HR, 0.36; 95% CI, 0.33-0.39), 3 years (HR, 0.42; 95% CI, 0.40-0.44), and 5 years (HR, 0.48; 95% CI, 0.47-0.50) after the index date compared with nonusers. A protective effect against AMD development was observed (HR, 0.58; 95% CI, 0.56-0.59) among NSAID users compared with nonusers. A protective effect against AMD development was observed among patients who were prescribed aspirin (HR, 0.72; 95% CI, 0.69-0.75) and those prescribed nonselective cyclooxygenase-2 inhibitors (HR, 0.41; 95% CI, 0.36-0.46) compared with their respective nonusers. A decreased risk of AMD was observed for both nonexudative (HR, 0.56; 95% CI, 0.55-0.58) and exudative (HR, 0.62; 95% CI, 0.59-0.65) AMD subtypes after index NSAID prescription compared with nonusers. CONCLUSIONS: A protective effect against future AMD development was suggested among patients prescribed NSAIDs compared with nonusers. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Hsu AY, Kuo HT, Liu DY, et al. Nonsteroidal Anti-inflammatory Drug Use and the Risk of Age-Related Macular Degeneration: Insights from a Multicenter Cohort Analysis. Ophthalmology. 2026. PMID: 42070633. doi:10.1016/j.ophtha.2026.04.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。